Amyloidosis refers to the disruption and damage to organs and tissues due to deposits of abnormal, insoluble amyloid fibrils, which are formed by the accumulation of misfolded proteins. Amyloid…
From disease basics to insightful analysis of market dynamics, Thyroid Carcinoma | Niche Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing…
Immune checkpoint inhibitors are the hottest drug class in oncology and are poised to continue revolutionizing the treatment algorithms of a wide range of solid-tumor and hematological malignancies…
Huntington’s disease (HD) is a neurodegenerative genetic disorder caused by an abnormal trinucleotide repeat in the Htt gene. Aggregation of the product of the mutant allele, mHtt, drives the…
Cystic fibrosis (CF) is a genetic disease affecting chloride transport in a variety of tissues, most notably the lungs and pancreas. It is caused by mutations in the cystic fibrosis transmembrane…
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine…
The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig…
From disease basics to insightful analysis of market dynamics, Heart Failure | Disease Landscape & Forecast | G7 provides comprehensive disease coverage addressing critical aspects of the heart…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…
Schizophrenia is an often disabling psychiatric disease whose core treatment consists of years up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical…
The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The AD population is poised to grow…
Multiple label expansions of premium-priced agents and the launch of four novel therapies will fuel the significant growth of the multiple myeloma market over the ten-year forecast period. The…
Until recently, SCCHN treatment lacked promising late-phase agents; the only targeted therapy approved for the indication was Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux. However, the…
DRG anticipates the next ten years to be an exciting time in the hemophilia space, as the number of treatment options grow for patients with, and without, inhibitors. The hemophilia A pipeline is…
Abstract Introduction: The Emerging Biosimilars Overview offers extensive coverage of the global biosimilar development landscape. We track over 350 currently available and novel biosimilar…